SJSTORY Blog

비트코인이 폭등하다가 폭락후 다시 이틀만에 제자리를 찾아가고있다
일본은 국가에서 인정하기 시작해서 세금도 낼수있다고 하니 비트코인이 미래의 재화로 점점 자리잡아가고 있는것같다

먼저 거래소에서 주식처럼 사서 오를때 팔면 되기도 하고 채굴기를 구입해서 직접 채굴할수도 있다
채굴 개념이 어려운데 수학문제 풀어서 맞추면 사탕하나 준다고 생각하면 된다
거래소는 빗썸 코인원 ... 몇군데 있고
채굴기는 가성비 Geforce 1060 / 성능 1080ti를 6웨이로 많이 구성하고 있다

이것저것 복잡하면 서버를 임대해서 평생 채굴해주는 클라우드 마이닝을 하면 된다
단 클라우드다 보니 먹튀의 위험이 있으므로 항상 조삼하고 큰곳만 적당한 금액으로 하자

제네시스 마이닝이 나름 유명해서 시작해 보았다
한글 사이트도 제공해서 어려움은 없고 카드결제로 해시파워(채굴성능)을 구입하면 유지비만 받고 평생 채굴해준다고 한다

https://www.genesis-mining.com​

가입하고 해시파워를 구매하면 되는데 비트코인 1TH구매에 매일 매일 300원정도 들어온다고 한다 물론 비트코인은 오르고 있으니 그 가치는 오를것이다

구입할때 프로모션코드 넣으면 3%할인을 해주고 있다
결제할때 쿠폰번호 넣는곳에 ​eCfSQs 넣은뒤 결제하면 된다

프로모션 코드를 입력하면 결제금액에서 3% 할인이 되며 당사자에게는 2.5%의 파워업그레이드를 받을 수 있다

​

​

​

History

Feb. 2002 Celltrion is founded

Jun. 2005 Supply Agreement with a US pharmaceutical company

Jul. 2005 Mechanical completion of Plant 1 (capacity: 50,000L)

Dec. 2007 Plant 1 receives cGMP facility approval by the US FDA

Aug. 2009 IND approval of Herzuma for breast cancer treatment

Oct. 2009 Completion of global sales network

Mar. 2010 IND approval of Remsima for rheumatoid arthritis, ankylosing spondylitis treatment

May. 2010 Strategic direct investment by Temasek

Dec. 2010 Mechanical completion of Plant 2 (capacity: 90,000L)

Dec. 2011 IND approval of biosimilar candidate CT-P10 for rheumatoid arthritis and Non Hodgkin’s lymphoma

Jul. 2012 Remsima approved by Korea Ministry of Food and Drug Safety (MFDS, formerly, KFDA)

Apr. 2013 IND approval of CT-P27 (for universal influenza treatment)

Aug. 2013 Remsima approved by the EMA

Nov. 2013 Completion of global clinical trial phase 1 for CT-P27

Jan. 2014 Herzuma approved by the MFDS, Remsima approved by Health Canada

Jul. 2014 Remsima approved by MHLW (Japan), MoH (Turkey)

Aug. 2014 Completion of global clinic trial phase 2a for CT-P27

Feb. 2015 Remsima launched in Europe (12 countries including Germany, France, England, Italy, Spain)

Apr. 2015 Remsima? approved by ANVISA (Brazil), INHRR (Venezuela)

Oct. 2015 TruximaTM (CT-P10) filed for EMA approval

Dec. 2015 TruximaTM (CT-P10) filed for MFDS approval

Apr. 2016 Remsima? approved by the US FDA

Since Celltrion's foundation in 2002, Celltrion has concentrated Celltrion's investments in human resources, facilities and technologies with the singular goal of becoming a global biopharmaceutical company that develops, manufactures and markets affordable advanced therapeutics based on recombinant DNA and molecular biology.

As of 2016, Celltrion has obtained marketing authorizations for Remsima and Herzuma in Korea, Celltrion's two biosimilar monoclonal antibodies (mAbs)


Remsima (or Inflectra), the world’s first biosimilar mAb, has already been approved not only in Korea but also in many countries around the world, including those in Europe and the US.

Herzuma, the world’s first anti neoplastic biosimilar mAb, has thus far been approved in Korea. Application for its approval is planned to be submitted in other countries.

Truxima, Celltrion's Rituxan biosimilar, is awaiting approval by the European Medicines Agency while Herzuma, its Herceptin biosimilar, is in the final stages of phase-III clinical trials and preparing for EMA approval procedures.

Most notably, in August 2014, Celltrion completed phase 2a clinical trial for CT-P27, universal influenza antibody drug, a novel therapeutic antibody under development for treatment against various types of influenza viruses. CT-P27, a cocktail injectable made up of two different monoclonal antibodies developed by Celltrion, has been drawing keen interests from the US and Chinese governments for targeting neutralization of a broad spectrum of influenza viruses including seasonal strains and potential pandemic strains. Through its mode of action which is distinct from existing influenza treatments, CT-P27 aims to neutralize even those influenza viruses that have become resistant to currently existing neuraminidase inhibitors.

Celltrion projects that its non-clinical and clinical studies have the potential to demonstrate CT-P27 as possible treatment of various types of influenza virus infection.

Celltrion's bid to become a world-class biopharmaceutical company continues today with Celltrion's eyes set firmly on serving the needs of patients through development of affordable biosimilar mAbs and innovative next-generation drugs.

출처 : http://m.thinkpool.com/item/discuss/pdsRead.jsp?code=068270&name=stock_bbs&mcd=I0C&ctg=&slt=&key=&page=1&number=10057124&i_max=00100572289999